Skip to main content

PD-L1/B7-H1 Products

PD-L1, also known as B7-H1 and CD274, is an approximately 65 kDa transmembrane glycoprotein in the B7 family of immune regulatory molecules. PD-L1 is expressed on inflammatory-activated immune cells including macrophages, T cells, and B cells, keratinocytes, endothelial and intestinal epithelial cells, as well as a variety of carcinomas and melanoma. PD-L1 protein binds to T cell B7-1/CD80 and PD-1.

It suppresses T cell activation and proliferation and induces the apoptosis of activated T cells. It plays a role in the development of immune tolerance by promoting T cell anergy and enhancing regulatory T cell development. PD-L1 favors the development of anti-inflammatory IL-10 and IL-22 producing dendritic cells and inhibits the development of Th17 cells. In cancer, PD-L1 provides resistance to T cell mediated lysis, enhances EMT, and enhances the tumorigenic function of Th22 cells. Many tumors overexpress PD-L1 protein making the PD-1:PD-L1 interaction central to several successful cancer immunotherapy approaches.

Products:

Show More

1142 results for "PD-L1/B7-H1" in Products

1142 results for "PD-L1/B7-H1" in Products

PD-L1/B7-H1 Products

PD-L1, also known as B7-H1 and CD274, is an approximately 65 kDa transmembrane glycoprotein in the B7 family of immune regulatory molecules. PD-L1 is expressed on inflammatory-activated immune cells including macrophages, T cells, and B cells, keratinocytes, endothelial and intestinal epithelial cells, as well as a variety of carcinomas and melanoma. PD-L1 protein binds to T cell B7-1/CD80 and PD-1.

It suppresses T cell activation and proliferation and induces the apoptosis of activated T cells. It plays a role in the development of immune tolerance by promoting T cell anergy and enhancing regulatory T cell development. PD-L1 favors the development of anti-inflammatory IL-10 and IL-22 producing dendritic cells and inhibits the development of Th17 cells. In cancer, PD-L1 provides resistance to T cell mediated lysis, enhances EMT, and enhances the tumorigenic function of Th22 cells. Many tumors overexpress PD-L1 protein making the PD-1:PD-L1 interaction central to several successful cancer immunotherapy approaches.

Products:

Show More

Analyzed by SEC-MALS

Recombinant Monoclonal Antibody

Recombinant Monoclonal Antibody

Recombinant Monoclonal Antibody

Recombinant Monoclonal Antibody

Recombinant Monoclonal Antibody

Recombinant Monoclonal Antibody

Recombinant Monoclonal Antibody

Recombinant Monoclonal Antibody

Recombinant Monoclonal Antibody

Recombinant Monoclonal Antibody

Recombinant Monoclonal Antibody

Recombinant Monoclonal Antibody

Recombinant Monoclonal Antibody

Recombinant Monoclonal Antibody

Recombinant Monoclonal Antibody

Recombinant Monoclonal Antibody

Recombinant Monoclonal Antibody

Recombinant Monoclonal Antibody

Recombinant Monoclonal Antibody

Recombinant Monoclonal Antibody

Recombinant Monoclonal Antibody

Results Per Page
5 10 25 50
/ 46